AsianScientist (Jan. 21, 2019) – Takeda Pharmaceutical Company Limited (Takeda) has announced the completion of its acquisition of global biotechnology firm Shire plc (Shire).
“We are pleased to have completed the acquisition several months earlier than expected, which was enabled through the hard work of our respective organizations and the smooth receipt of regulatory clearances,” said Mr. Christophe Weber, president and CEO of Takeda.
“This marks a significant moment in Takeda’s history and is an exciting step forward as we accelerate our transformation journey to deliver highly-innovative medicines to patients around the world with expanded scale and geographical footprint.”
Takeda’s R&D efforts are focused on its four therapeutic areas of oncology, gastroenterology, neuroscience and rare diseases, with targeted R&D investment also committed to plasma-derived therapies and vaccines. With the acquisition of Shire, the combined annual revenue of Takeda now exceeds US$30 billion.
“The operating model we established in September last year [2018] has set a clear framework for our integration plans, and we have a highly skilled and dedicated integration team leading the process,” said Weber.
———
Source: Takeda; Photo: Shutterstock.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
